| |
Download our guide to learn how to navigate the complex European landscape and gain insights on how late-stage customization could make your European distribution simpler and more efficient. Download now. 
|
|
Today’s Big NewsOct 19, 2023 |
| By Nick Paul Taylor Roche’s vision of developing an oral diabetic retinopathy treatment has taken a hit, with the drugmaker stopping development of vicasinabin after completing phase 2. The CB2 agonist was discarded as part of a cull that also saw Roche pull back from its CEAxCD3 bispecific candidate cibisatamab. |
|
|
|
By Max Bayer Beam Therapeutics is laying off about 100 employees and sunsetting CAR-T development as a lead sickle trial continues to sluggishly progress. The company says the cost cuts should extend the cash runway into 2026. |
By Max Bayer While most of the attention on CRISPR Therapeutics centers on the company’s Vertex-partnered cell therapy and looming FDA advisory committee meeting, Alex Harding, M.D., is cooking up the biotech's next wave of deals. |
Sponsored by Tanvex CDMO Reacting to the growth of biotherapeutics, Tanvex BioPharma USA, Inc., is set to launch Tanvex CDMO, a full-service CDMO specializing in mammalian- and microbial-derived biologics and biosimilars. |
|
Best-in-class thermostability and excellent inhibitor tolerance deliver compatibility across a range of clinically relevant samples and superior results in pathogen detection assays. Lyophilization-friendly formats available. Learn more. .png)
|
|
By Nick Paul Taylor Eli Lilly is hoovering up European antibody-drug conjugate startups. Months after making a move for Emergence Therapeutics, Lilly has struck a deal to buy one of its partners, Mablink Bioscience, to add more ADC technology and drug candidates to its portfolio. |
By Gabrielle Masson An Array BioPharma investor is facing insider trading allegations, with criminal and civil cases accusing him of unlawfully trading stock options after learning from his wife—an Array employee—that Pfizer might acquire the biotech. |
By James Waldron The buzz around HER3-targeting antibody drug conjugates continues to grow. Only a week after BioNTech got in on the action, Endeavor has secured the rights to Hummingbird Bio's preclinical contender. |
By James Waldron With a cash runway that could run out of tarmac in the next six months, British biotech Freeline Therapeutics is considering the offer of a buyout from its majority shareholder Syncona. |
By James Waldron Basilea Pharmaceutica is hoping to have better luck with its second attempt to build out its anti-infective pipeline, handing over $2 million for Gravitas Therapeutics’ clinical-stage antifungal. |
By Joseph Keenan Avania has continued to expand its expertise as a medtech-focused CRO with the acquisitions of Hull Associates and Ironstone Product Development. |
By Fraiser Kansteiner Novo Nordisk's hugely popular diabetes and weight-loss meds have attracted their share of counterfeits. Now, British and European drug authorities are warning that they've discovered falsified Ozempic pens on their home turf. |
By Andrea Park Though Novo Nordisk continues to rake in the massive profits from its blockbuster drugs Ozempic, Wegovy, Victoza and Saxenda—which are prescribed to treat obesity and Type 2 diabetes—the Danish drugmaker is still looking for other approaches. |
By Kevin Dunleavy After trimming an early-stage Crohn’s disease candidate from its pipeline this year, Takeda is dealing with the failure of another of its therapies in a related indication. Alofisel (daradstrocel), a stem cell therapy designed to treat one of the most debilitating complications of Crohn’s—complex perianal fistulas (CPF)—has come up short in a phase 3 trial. |
By Paige Minemyer Waymark, a Medicare-focused provider enablement company, has secured $42 million in fresh funding that it plans to use to continue scaling its offering. |
Fierce podcasts Don’t miss an episode |
| In this episode of "The Top Line," Fierce Biotech's Annalee Armstrong engages in a conversation with Howard Fillit, M.D., an expert in the field of Alzheimer's research and the co-founder and chief science officer at the Alzheimer's Drug Discovery Foundation. They delve into the pioneering work being done in Alzheimer's research, discuss the latest breakthroughs, and explore the ongoing efforts to combat this complex disease. |
|
|---|
|
|
|
Learn how to improve yield and reproducibility with advanced sample prep for a variety of multiomics use cases, especially for suboptimal biospecimens. See how to get quality results from complex samples thanks to key innovations in ultrasonication. Learn more. 
|
|
Whitepaper From trial site feasibility and patient populations to data analysis, generative AI has the potential to revolutionize drug discovery and clinical trial recruitment at both the therapeutic area and indication level. Sponsored by: H1 |
eBook Learn how to get better results from suboptimal biospecimens for NGS and protein analysis. Sponsored by: Covaris |
Whitepaper Accelerate drug discovery with high-performance computing (HPC) powered by the cloud Sponsored By: AWS, NVIDIA, and Rescale |
Whitepaper Cell and gene therapy development has exploded, with Q4 2022 showing more FDA approvals than over the past five years combined.[1] Sponsored by: Thermo Fisher Scientific |
Whitepaper Uncover the keys to efficient bioprocessing, including how outsourcing quality management can reduce risk, save time and money, and expedite biologics development. Sponsored by: Thermo Scientific™ Production Chemicals and Services |
Webinar Embark on an in-depth journey through the pivotal Make-Test-Decide Workflow, where collaboration and data-driven decisions play a paramount role in the intricate landscape of drug discovery. Watch now to learn how cloud implementation fosters accessibility and collaboration, revolutionizing research across locations and companies. Sponsored by: Revvity Signals |
Whitepaper Economic and regulatory factors are making biopharma supply chains more complex in the EU. This paper explores strategies that biopharma companies can use to better manage complexity, cost, and risk. Presented by: AIM, the supply chain leader for life science entrants and midsize life science companies |
Whitepaper From Assay Development Through Large Molecule Development. Streamline your R&D workflows and gain valuable insights with our Biology Solutions Brochure. Download now to discover how to control your laboratory workflows across various assay techniques, modalities, and data types. Sponsored by: Revvity Signals |
eBook Emulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
| Edison Ballroom, New York City |
|
|
| |
|
